<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1978">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681092</url>
  </required_header>
  <id_info>
    <org_study_id>NL2020-005997-82</org_study_id>
    <nct_id>NCT04681092</nct_id>
  </id_info>
  <brief_title>Anti-COVID19 AKS-452 - ACT Study</brief_title>
  <acronym>ACT</acronym>
  <official_title>Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akston Biosciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combinatorial phase I/II safety, tolerability and immunogenicity single center open-label&#xD;
      clinical study of AKS-452 COVID-19 vaccination study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a combinatorial single-center open-label phase I and II clinical&#xD;
      study design:&#xD;
&#xD;
      I. a phase I dose-finding and safety / tolerability study combined with, II. a phase II&#xD;
      safety / efficacy study on the biological activity of AKS-452 against COVID-19.&#xD;
&#xD;
      To warrant more extensive development towards a phase III clinical study. The study will have&#xD;
      a duration of approximately 4 months and will be executed at the University Medical Center&#xD;
      Groningen, The Netherlands supported by the subsidizing party Akston Biosciences.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 18, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single-center, open-label, combinatorial safety, tolerability and exploratory efficacy</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety / Tolerability</measure>
    <time_frame>35 days</time_frame>
    <description>CTCAE-scoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>180 days</time_frame>
    <description>Antibody response COVID-19</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>AKS-452 s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of pre-defined dose (45 ug, 250 uL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKS-452 i.m. (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of pre-defined dose (45 ug, 250 uL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKS-452 i.m. (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of pre-defined dose (90 ug, 500 uL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AKS-452</intervention_name>
    <description>s.c. or i.m. vaccination</description>
    <arm_group_label>AKS-452 i.m. (A)</arm_group_label>
    <arm_group_label>AKS-452 i.m. (B)</arm_group_label>
    <arm_group_label>AKS-452 s.c.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        SARS-CoV-2 serology by Akston (a quantitative anti-SARS-Cov-2 SP/RBD-specific IgG ELISA):&#xD;
&#xD;
          -  Undetectable or &lt; 5 μg/mL titer and no known prior SARS-Cov-2 infection&#xD;
&#xD;
               -  Body mass index (BMI) between 19.0 and 30.0 kg/m2, inclusive&#xD;
&#xD;
               -  General good health, without significant medical illness, as determined via&#xD;
                  physical exam findings, ECG or vital signs&#xD;
&#xD;
          -  Note: one retest of vital functions and ECG is allowed within the screening window&#xD;
&#xD;
             - No clinically significant laboratory abnormalities as determined by the investigator&#xD;
&#xD;
          -  Note: one retest of lab tests is allowed within the screening window&#xD;
&#xD;
               -  Informed Consent Form signed voluntarily before any study-related procedure is&#xD;
                  performed, indicating that the subject understands the purpose and procedures&#xD;
                  required for the study and is willing to participate in the study&#xD;
&#xD;
               -  Willing to adhere to the prohibitions and restrictions specified in this protocol&#xD;
&#xD;
               -  Non-smoker (including prior smokers having stopped smoking for more than 3 months&#xD;
                  at time of screening) or non-habitual smoker (habitual smokers are persons who&#xD;
                  smoke more than 4 cigarettes or other tobacco products on a weekly basis) and&#xD;
                  agree to not use tobacco products during confinement.&#xD;
&#xD;
               -  Negative alcohol breath test and urine drug screen at screening and upon check-in&#xD;
                  at the clinical site.&#xD;
&#xD;
               -  Negative hepatitis panel (including hepatitis B surface Ag and anti-hepatitis C&#xD;
                  virus Abs) and negative human immunodeficiency virus Ab and Ag screens at&#xD;
                  screening&#xD;
&#xD;
               -  Female subjects should fulfil one of the following criteria:&#xD;
&#xD;
          -  At least 1 year post-menopausal (amenorrhea &gt;12 months and/or follicle stimulating&#xD;
             hormone &gt;30 mIU/mL) at screening;&#xD;
&#xD;
          -  Surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation);&#xD;
&#xD;
          -  Will use adequate forms of contraceptives from screening to discharge.&#xD;
&#xD;
             - Female subjects of childbearing potential and male subjects who are sexually active&#xD;
             with a female partner of childbearing potential must agree to the use of an effective&#xD;
             method of birth control from screening to discharge&#xD;
&#xD;
          -  Note: medically acceptable methods of contraception that may be used by the subject&#xD;
             and/or partner include combined oral contraceptive, contraceptive vaginal ring,&#xD;
             contraceptive injection, intrauterine device, etonogestrel implant, double barrier,&#xD;
             sterilization and vasectomy&#xD;
&#xD;
             - Female subject has a negative pregnancy test at screening and upon check-in at the&#xD;
             clinical site.&#xD;
&#xD;
          -  Note: pregnancy testing will consist of a serum pregnancy test at screening and urine&#xD;
             pregnancy tests at other (dosing) visits, in all women.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A potential subject who meets any of the following criteria will be excluded from&#xD;
        participation in this study:&#xD;
&#xD;
          -  Pregnant of breastfeeding females&#xD;
&#xD;
          -  Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,&#xD;
             hematologic, rheumatologic, endocrine, autoimmune, or renal disease&#xD;
&#xD;
          -  Any laboratory test which is abnormal, and which is deemed by the Investigator(s) to&#xD;
             be clinically significant&#xD;
&#xD;
          -  Behavioral or cognitive impairment or psychiatric disease that in the opinion of the&#xD;
             investigator affects the ability of the subject to understand and cooperate with the&#xD;
             study protocol&#xD;
&#xD;
          -  Current alcohol/illicit drug/nicotine abuse or addiction: history or evidence of&#xD;
             current drug use or addiction (positive drug screen for amphetamines, barbiturates,&#xD;
             benzodiazepines, cannabinoids, cocaine, or opiates) or excessive use of alcohol at&#xD;
             screening and Day -2.&#xD;
&#xD;
          -  Presence of any febrile illness (T &gt; = 38.0°C or lab confirmed viral disease (PCR)) or&#xD;
             symptoms suggestive of a viral respiratory infection within 1 weeks prior to&#xD;
             vaccination&#xD;
&#xD;
          -  Use of corticosteroids (excluding topical preparations for cutaneous or nasal use) or&#xD;
             use of immunosuppressive drugs within 30 days before inoculation&#xD;
&#xD;
          -  A history of anaphylaxis, history of allergic reaction to vaccine, known allergy to&#xD;
             one of the components in AKS-452. Mild allergies without angio-oedema or treatment&#xD;
             need can be included if deemed not to be of clinical significance (including but not&#xD;
             limited to allergy to animals or mild seasonal hay fever)&#xD;
&#xD;
          -  A history of asthma within the past 10 years, or a current diagnosis of asthma or&#xD;
             reactive airway disease associated with exercise&#xD;
&#xD;
          -  Receipt of a licensed vaccine within 4 weeks prior to viral inoculation&#xD;
&#xD;
          -  Received any experimental SARA-CoV-2 vaccine or drug&#xD;
&#xD;
          -  Receipt of blood or blood-derived products (including immunoglobulin) within 6 months&#xD;
             prior to vaccination.&#xD;
&#xD;
          -  Receipt of another investigational agent within 30 days or 5 times the product&#xD;
             half-life (whichever is longest) prior to vaccination&#xD;
&#xD;
          -  Shares household with /works with immunocompromised individual(s), adults with&#xD;
             significant cardiopulmonary disease, persons with significant asthma,&#xD;
             institutionalized elderly or elderly with functional disability&#xD;
&#xD;
          -  Deprived of freedom by an administrative or court order or in an emergency setting -&#xD;
             Any condition that in the opinion of the principal investigator (PI) would jeopardize&#xD;
             the safety or rights of a person participating in the trial or would render the person&#xD;
             unable to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Gooitzen M van Dam, MD, PhD</last_name>
      <phone>+31622914614</phone>
      <email>g.m.van.dam@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Schelto Kruijff, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hendrikus H Boersma, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Schelto Kruijff, MD PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>safety</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>dose-finding</keyword>
  <keyword>exploratory efficacy</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

